Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP reduced its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 18.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 134,518 shares of the biopharmaceutical company's stock after selling 30,600 shares during the quarter. Two Sigma Advisers LP owned approximately 0.10% of Dynavax Technologies worth $1,718,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in shares of Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 1,169 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 2,034 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Dynavax Technologies during the fourth quarter worth $71,000. Nisa Investment Advisors LLC increased its position in shares of Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after purchasing an additional 1,076 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Dynavax Technologies by 68.7% during the 4th quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 2,857 shares during the last quarter. Institutional investors own 96.96% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on DVAX. The Goldman Sachs Group dropped their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. Wall Street Zen lowered Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reissued a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, JMP Securities decreased their price target on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $24.00.

Dynavax Technologies Stock Performance

Shares of NASDAQ:DVAX traded up $0.05 during trading on Friday, hitting $9.81. The stock had a trading volume of 1,937,331 shares, compared to its average volume of 2,207,858. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 12-month low of $9.22 and a 12-month high of $14.63. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 54.50 and a beta of 1.26. The stock has a 50-day simple moving average of $11.00 and a two-hundred day simple moving average of $12.32.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.14). The business had revenue of $68.16 million for the quarter, compared to analysts' expectations of $70.01 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, equities research analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.